Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.
Publication|Articles|June 12, 2025
- Spring 2025
- Volume 19
- Issue 01
Spring 2025 Quiz: Test Your Pharmacy Knowledge!
Key Takeaways
- Personalized treatment strategies have advanced the management of lung cancer brain metastases, improving patient outcomes with targeted therapies and immunotherapies.
- Stereotactic radiosurgery and whole-brain radiation therapy are evolving in their roles due to novel systemic therapies.
This quiz was created in collaboration with PTCE™.
Advertisement
Which of the following drug classes is included in the Expert Consensus Decision Pathway guideline–directed medical therapy for heart failure?
Articles in this issue
over 1 year ago
Resident Mental Health Mattersover 1 year ago
Navigating the Fellowship Journey: A Road Map to Successover 1 year ago
A Student Pharmacist’s Guide to HIV Medicationsover 1 year ago
Pharmacist Roles in a Correctional InstitutionAdvertisement
Related to this article
Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
Increasingly, pharmacists are leading the obesity management team.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.
The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
4
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
5